Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Ultragenyx Pharmaceutical (RARE) EPS (Basic): 2014-2024

Historic EPS (Basic) for Ultragenyx Pharmaceutical (RARE) over the last 11 years, with Dec 2024 value amounting to -$6.29.

  • Ultragenyx Pharmaceutical's EPS (Basic) fell 29.29% to -$1.81 in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.93, marking a year-over-year increase of 7.20%. This contributed to the annual value of -$6.29 for FY2024, which is 23.76% up from last year.
  • According to the latest figures from FY2024, Ultragenyx Pharmaceutical's EPS (Basic) is -$6.29, which was up 23.76% from -$8.25 recorded in FY2023.
  • Over the past 5 years, Ultragenyx Pharmaceutical's EPS (Basic) peaked at -$3.07 during FY2020, and registered a low of -$10.12 during FY2022.
  • Over the past 3 years, Ultragenyx Pharmaceutical's median EPS (Basic) value was -$8.25 (recorded in 2023), while the average stood at -$8.22.
  • As far as peak fluctuations go, Ultragenyx Pharmaceutical's EPS (Basic) skyrocketed by 56.88% in 2020, and later slumped by 118.24% in 2021.
  • Over the past 5 years, Ultragenyx Pharmaceutical's EPS (Basic) (Yearly) stood at -$3.07 in 2020, then plummeted by 118.24% to -$6.70 in 2021, then plummeted by 51.04% to -$10.12 in 2022, then climbed by 18.48% to -$8.25 in 2023, then rose by 23.76% to -$6.29 in 2024.